Title Image

Clinical trials


Increasingly, new medicines for the treatment of AA and PNH are being developed. Some of them are already tested in clicial trials, others will follow. Maybe you thought about participating in a clinical trial or were invited to do so. Before you make a decision it is important that you know what a participation would mean for you. What pros and cons could arise? What are the potential risks? In any case you should consider your decison carefully.

Below you will find brief explanations of some of the terms frequently used in connection with therapy studies.



    Therapeutic studies serve to test a new treatment concept or drug. Usually a newly developed drug is compared with the standard therapy or a sham drug (without effect, placebo).

    The sponsor of a clinical trial is either a pharmaceutical company, or the trial is planned by doctors, researchers or university research groups, then it is called an academic trial (Investor-Initiated Trial, IIT).

    Inclusion/exclusion criteria regulate who can take part in a study and at what stage, for example the age, sex and health status of a person.

    Before a study is approved, it must be approved by an ethics committee. The ethics committee examines the study with regard to its medical, scientific and ethical significance, compliance with legal requirements and the qualifications of the persons and organisations conducting the study.

    A proband insurance serves as a cover in case of health damages caused by the treatment in the study. The insurance pays for rehabilitation and, if necessary, required home reconstruction measures as well as financial losses, for example in the event of reduced earning capacity.


    Studies are divided into different criteria, one or more of which may apply to a study:

    The results of the trial group that receives the drug under investigation are compared with the results of a control group that receives, for example, the standard therapy.

    Participants are randomly assigned to one of the groups (arms).

    (single) blind
    The participant does not know whether he or she is receiving the trial drug.

    Neither the doctor nor the participant knows whether the participant is receiving the study drug or the comparison drug.



    In phase I of a study, the tolerability and safety of the study drug is tested. This includes the effect of the drug and its absorption, distribution and metabolism in the body, as well as determining the correct dose. In this phase, only a small group of volunteers takes part.

    Based on the findings from phase I, the drug will be administered to a larger number of test persons in phase II. The aim is to confirm the correct dose determined in phase I and to document the side effects accurately.

    In phase III, the efficacy and safety of the drug is to be proven. Only with this proof can the drug be approved. This part of the trial is often conducted at several centres.

    Phase IV begins after approval. During this phase, the long-term tolerance and side effects are investigated, which were not observed in previous phases due to their possibly rare occurrence. Since all patients receiving the drug are included in phase IV, a comparatively large number of patients is taken into account.




    EMAA (Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anaemia) for patients with moderate Aplastic Anaemia (MAA) who need to be treated with ciclosporin
    Comparison of Eltrombopag + Ciclosporin with Placebo + Ciclosporin

  • Phase 3
  • location: Ulm
  • Identifier NCT02773225 or EudraCT 2014-000174-19

  • RACE (horse ATG + ciclosporin + eltrombopag versus horse ATG + ciclosporin) for patients with severe or very servere Aplastic Anaemia (SAA or vSAA)

  • Phase 3
  • locations: abroad only, e.g. Basel (Switzerland)
  • Identifier NCT02099747



    APL2-307 (Pegcetacoplan) (Long Term Safety and Efficacy Extension Study)

  • C3 complement inhibitor
  • Phase 3
  • subcutaneous application
  • locations: Aachen, Essen, Hamburg, Ulm
  • Identifier NCT03531255 or EudraCT 2019-001106-23

  • LNP023 (Iptacopan) (Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH))

  • Factor B inhibitor
  • Phase 2
  • oral application
  • location: Essen
  • Identifier NCT03439839 or EudraCT 2017-000888-33

  • BP39144 (Crovalimab) (An Adaptive Phase I/II Study to Assess Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Crovalimab in Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH))

  • C5 complement inhibitor
  • Phase 1/2
  • subcutaneous application
  • locations: Aachen, Essen, Riesa, Ulm
  • Identifier NCT03157635 or EudraCT 2016-002128-10

  • BO42161 (Crovalimab), “COMMODORE 1” (A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors. (COMMODORE 1))

  • C5 complement inhibitor
  • Phase 3
  • subcutaneous application
  • loctions: Aachen, Essen, Riesa, Ulm
  • Identifier NCT04432584 or EudraCT 2020-000597-26

  • BO42162 (Crovalimab), “COMMODORE 2” (A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors. (COMMODORE 2))

  • C5 complement inhibitor
  • Phase 3
  • subcutaneous application
  • locations: Essen, Riesa, Ulm
  • Identifier NCT04434092 or EudraCT 2019-004931-21